EURORDIS-Rare Diseases Europe

EURORDIS-Rare Diseases Europe An alliance of patient organisations improving the lives of all people living with rare diseases.

02/09/2026

🔬 Rare disease research moves forward when experience and expertise come together.

Research can deepen our understanding of rare diseases, support earlier and more accurate diagnosis, and contribute to the development of new treatments. But true progress depends on bringing patients with lived experience into the heart of the research process.

📊 Rare Barometer captures the realities and experiences of people living with rare diseases across areas including diagnosis, treatment and care.

🎓 Through the Open Academy, patient advocates build their knowledge of the rare disease research environment and opportunities to get involved.

🧬 The ePAG Transversal Working Group on Research and Registries develops patient advocates’ understanding of relevant ERN clinical and basic research topics.

🤝 And the EURORDIS Round Table of Companies creates a space for pharmaceutical and biotech companies to engage with the rare disease community and collaborate on research, development and access to treatments.

đź”— Discover more about our work on rare disease research: https://go.eurordis.org/rare-research-eurordis

🎓 They’re back! Applications for the 2027 EURORDIS Open Academy x ERDERA Schools are now open.Bringing together online l...
01/09/2026

🎓 They’re back! Applications for the 2027 EURORDIS Open Academy x ERDERA Schools are now open.

Bringing together online learning, webinars and face-to-face training, the Open Academy Schools equip rare disease patient advocates and researchers with the knowledge, skills and confidence to contribute meaningfully to rare disease research.

So, where do you want to deepen your knowledge?

đź’Š From research to medicine? The Medicines Research & Development School explores the medicines development pathway.

🔬 From scientific discovery to impact? The Scientific Innovation & Translational Research School focuses on translating research into meaningful impact.

Throughout the programme, participants follow learning specific to their chosen school, before coming together in Barcelona for dedicated and joint sessions. It’s an opportunity for researchers and patient representatives to learn with and from one another, bringing different perspectives to rare disease research.

Now in their third year under ERDERA, the schools bring together expertise from across the research, regulatory, industry and patient communities, with practical learning designed to support participants beyond the programme.

📍 Barcelona | 7–10 June 2027
🎓 80 places available – 40 per School
👤Free of charge for patient advocates, thanks to ERDERA funding

Which School is right for you? 👉 Discover the programmes, check your eligibility and apply: https://go.eurordis.org/OpenAcademy2027

🧬 What’s happening in clinical trials for osteogenesis imperfecta (OI)?The Osteogenesis Imperfecta Federation Europe (OI...
31/08/2026

🧬 What’s happening in clinical trials for osteogenesis imperfecta (OI)?

The Osteogenesis Imperfecta Federation Europe (OIFE) is bringing the OI community together for its Clinical Trial Update 2026 webinar, offering an overview of the ongoing clinical trials and where they currently stand.

The session is open to people living with OI and their families, as well as professionals and anyone interested in OI-related research.

đź“… 13 October 2026

⏰ 20:00–21:30 CET

👉 Learn more and register: https://go.eurordis.org/trial-update-oife

✨ There's still time to make sure great work gets the recognition it deserves!Don't miss your chance to recognise the pe...
27/08/2026

✨ There's still time to make sure great work gets the recognition it deserves!

Don't miss your chance to recognise the people, organisations and partnerships making a real difference for the rare disease community.

Whether it's an inspiring volunteer, a dedicated researcher, an innovative healthcare team, a passionate advocate, a pioneering company or a powerful partnership, the EURORDIS Black Pearl Awards celebrate those working to improve the lives of people living with a rare disease.

Know someone who deserves to be celebrated? Don't let this opportunity pass them by. And if one of our award categories reflects your own work, you can even nominate yourself!

đź“… Nominations close on Friday, 4 September 2026.

👉 Submit your nomination today: https://go.eurordis.org/BPA2027

In association with Ireland’s Presidency of the Council of the European Union, Rare Diseases Ireland is bringing people ...
26/08/2026

In association with Ireland’s Presidency of the Council of the European Union, Rare Diseases Ireland is bringing people together from across Europe to explore how we can accelerate the journey from rare disease research to innovation and adoption, with patients as proactive partners every step of the way.

Taking place in Dublin on 13 November, the event will explore the growing momentum towards a coordinated EU Action Plan for Rare Diseases, the role of the Biotech Act in strengthening European innovation and competitiveness, and what becomes possible when people living with rare diseases are true partners in research and innovation.

With the right policy environment, stronger coordination and meaningful patient partnership, we can shorten the path from discovery to adoption, helping promising research reach patients faster, and translating innovation into better outcomes for our community.

đź“… Save the date: Friday 13 November 2026
📍 Radisson Blu Royal Hotel, Dublin, Ireland

More information, including the full programme and registration details, will follow: https://go.eurordis.org/eu-presidency-rdi

📊 What can better use of health data change for people living with a rare disease? A lot.When rare disease data is colle...
25/08/2026

📊 What can better use of health data change for people living with a rare disease? A lot.

When rare disease data is collected, connected and used effectively, it can help support earlier diagnosis, better research, more personalised care and access to expertise across borders.

And people living with rare diseases recognise that potential. In a EURORDIS Rare Barometer survey, 97% of respondents said they would be willing to share their health data to improve diagnosis, develop new treatments and advance research into their disease – when appropriate safeguards are in place.

But making the most of data and digital health also means understanding how these tools work, how data can be used safely, and what this means for the rare disease community.

🎓 Want to learn more? Enrol now in our two free Open Academy courses on data and digital health to build your knowledge at your own pace: https://go.eurordis.org/opendata-academy

👉 Learn more about EURORDIS' work on data and digital health: https://go.eurordis.org/data-health-eurordis

🤝 What does meaningful patient partnership in medicines development look like?It means engaging people living with a rar...
24/08/2026

🤝 What does meaningful patient partnership in medicines development look like?

It means engaging people living with a rare disease as equal partners, incorporating their perspectives and involving them throughout every stage of medicines development.

Formerly known as the Company Award for Patient Engagement, the EURORDIS Award for Patient Partnership in Medicines Development recognises those putting these principles into practice.

From research collaborations and public-private partnerships to pharmaceutical companies working alongside patient organisations, this award celebrates partnerships driving meaningful engagement in medicines development.

Do you know a partnership making a difference? Help us celebrate those leading the way! You still have time to submit your nomination!

👉 Submit now: https://go.eurordis.org/BPA2027

đź”— Better health data exchange could mean better research and care for people living with a rare disease. But across Euro...
21/08/2026

đź”— Better health data exchange could mean better research and care for people living with a rare disease. But across Europe, important barriers still stand in the way.

As part of the JARDIN Joint Action, a hackathon brought together 47 experts from 10 European countries to explore how existing standards, software and infrastructures could be adapted and reused to enable more effective and secure rare disease health data exchange.

A new paper, co-authored by Veronica Popa, our Digital Patient Engagement Manager, has now been published in the Data Science Journal sharing the outcomes of the hackathon and presenting approaches to improve data harmonisation, secure access and interoperability between healthcare providers, registries and European Reference Networks.

The work now moves towards further real-world evaluation and pilot testing, with the aim of informing future recommendations for health data exchange across Europe.

đź“– Read the full open-access paper: https://go.eurordis.org/jardinhackathon

👶 A baby’s chance of an early diagnosis shouldn’t depend on the country they are born in. Yet across Europe, it still ca...
20/08/2026

👶 A baby’s chance of an early diagnosis shouldn’t depend on the country they are born in. Yet across Europe, it still can.

Italy nationally screens for more than 40 conditions, whilst some EU countries screen for fewer than ten. For families, that can mean the difference between early answers and care, or years of uncertainty and preventable harm.

Earlier detection is possible. Now, stronger European cooperation could help ensure that all children can benefit from it, wherever they are born.

It’s time to move beyond a postcode lottery at birth.

đź”— Read our full article on why Europe needs a shared approach to newborn screening: https://go.eurordis.org/eurordis-newborn

18/08/2026

💊 For people living with a rare disease, the development of new therapies is only part of the challenge. But they must also be made available, accessible, and affordable – wherever someone lives.

Getting there means looking at the whole journey: from research and development to regulatory decisions, health technology assessment, pricing, reimbursement and, ultimately, access.

At EURORDIS, we work across this journey to bring the patient voice into decision-making spaces, helping to ensure that innovation translates into real access for people living with a rare disease.

🎓 Want to go deeper? Explore our Open Academy courses on market access and HTA, clinical trial ethics, and the European Medicines Agency: https://go.eurordis.org/eurordis-health-access

đź”— Learn more about our work on treatments: https://go.eurordis.org/eurordis-treatments

Adresse

96 Rue Didot
Paris
75014

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque EURORDIS-Rare Diseases Europe publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.

Raccourcis

Partager